Ken Fisher's LGND Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 108,926 shares of Ligand Pharmaceuticals Incorporated (LGND) worth $19.3 M, representing 0.01% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in LGND, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2014, adding 46,650 shares. Largest reduction occurred in Q1 2021, reducing 61,429 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Ligand Pharmaceuticals Incorporated (LGND) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ligand Pharmaceuticals Incorporated (LGND) Trades by Ken Fisher
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2014 | +36,908 | New Buy | 36,908 | $62.29 |
| Q3 2014 | -1,650 | Reduce 4.47% | 35,258 | $47.00 |
| Q4 2014 | +46,650 | Add 132.31% | 81,908 | $53.21 |
| Q2 2015 | -1,300 | Reduce 1.59% | 80,608 | $100.90 |
| Q3 2015 | -9,925 | Reduce 12.31% | 70,683 | $85.65 |
| Q4 2015 | -100 | Reduce 0.14% | 70,583 | $108.43 |
| Q2 2016 | +1,807 | Add 2.56% | 72,390 | $126.76 |
| Q4 2016 | -6,900 | Reduce 9.53% | 65,490 | $101.60 |
| Q1 2017 | -5,100 | Reduce 7.79% | 60,390 | $105.85 |
| Q2 2017 | -90 | Reduce 0.15% | 60,300 | $121.39 |
| Q3 2017 | -3,945 | Reduce 6.54% | 56,355 | $136.15 |
| Q4 2017 | -1,294 | Reduce 2.30% | 55,061 | $136.94 |
| Q1 2018 | -8,143 | Reduce 14.79% | 46,918 | $165.16 |
| Q2 2018 | -2,184 | Reduce 4.65% | 44,734 | $207.18 |
| Q3 2018 | -2,115 | Reduce 4.73% | 42,619 | $274.48 |
| Q4 2018 | +23,486 | Add 55.11% | 66,105 | $135.69 |
| Q1 2019 | +5,651 | Add 8.55% | 71,756 | $125.70 |
| Q2 2019 | +13,692 | Add 19.08% | 85,448 | $114.15 |
| Q3 2019 | +12,750 | Add 14.92% | 98,198 | $99.54 |
| Q4 2019 | -11,271 | Reduce 11.48% | 86,927 | $104.29 |
| Q1 2020 | -8,581 | Reduce 9.87% | 78,346 | $72.72 |
| Q2 2020 | -3,908 | Reduce 4.99% | 74,438 | $111.85 |
| Q3 2020 | -4,443 | Reduce 5.97% | 69,995 | $95.32 |
| Q4 2020 | -2,548 | Reduce 3.64% | 67,447 | $99.46 |
| Q1 2021 | -61,429 | Reduce 91.08% | 6,018 | $152.38 |
| Q2 2021 | +225 | Add 3.74% | 6,243 | $131.19 |
| Q3 2021 | +1,191 | Add 19.08% | 7,434 | $139.36 |
| Q4 2021 | -3 | Reduce 0.04% | 7,431 | $154.49 |
| Q1 2022 | +40 | Add 0.54% | 7,471 | $112.43 |
| Q2 2022 | -40 | Reduce 0.54% | 7,431 | $89.22 |
| Q3 2022 | +20,859 | Add 280.70% | 28,290 | $86.11 |
| Q4 2022 | +11,368 | Add 40.18% | 39,658 | $66.80 |
| Q1 2023 | +242 | Add 0.61% | 39,900 | $73.56 |
| Q2 2023 | -4,075 | Reduce 10.21% | 35,825 | $72.10 |
| Q3 2023 | -2,563 | Reduce 7.15% | 33,262 | $59.92 |
| Q4 2023 | +16,035 | Add 48.21% | 49,297 | $71.42 |
| Q1 2024 | +4,080 | Add 8.28% | 53,377 | $73.10 |
| Q2 2024 | -358 | Reduce 0.67% | 53,019 | $84.26 |
| Q3 2024 | +6,555 | Add 12.36% | 59,574 | $100.09 |
| Q4 2024 | +41,064 | Add 68.93% | 100,638 | $107.15 |
| Q1 2025 | +6,868 | Add 6.82% | 107,506 | $105.14 |
| Q2 2025 | -1,440 | Reduce 1.34% | 106,066 | $113.68 |
| Q3 2025 | +2,860 | Add 2.70% | 108,926 | $177.14 |
Ken Fisher's Ligand Pharmaceuticals Incorporated Investment FAQs
Ken Fisher first purchased Ligand Pharmaceuticals Incorporated (LGND) in Q2 2014, acquiring 36,908 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Ligand Pharmaceuticals Incorporated (LGND) for 46 quarters since Q2 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher's largest addition to Ligand Pharmaceuticals Incorporated (LGND) was in Q4 2014, adding 81,908 shares worth $4.36 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 108,926 shares of Ligand Pharmaceuticals Incorporated (LGND), valued at approximately $19.3 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Ligand Pharmaceuticals Incorporated (LGND) represents approximately 0.01% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher's peak holding in Ligand Pharmaceuticals Incorporated (LGND) was 108,926 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.